Value-Based Pricing of Resmetirom for Metabolic Dysfunction–Associated Steatotic Liver Disease
In this economic evaluation, resmetirom was not cost-effective at a $100 000/QALY WTP threshold. The conclusion was sensitive to model assumptions, especially the discontinuation rate. More data on the long-term effectiveness of resmetirom on MASLD progression and non-MASLD complications would be necessary to accurately determine the economic value of resmetirom.
Authors
- Srinivasan Dasarathy (ORCID: https://orcid.org/0000-0003-1774-0104)
- Michael B. Rothberg (ORCID: https://orcid.org/0000-0002-2063-1876)
- Phuc Le (ORCID: https://orcid.org/0000-0003-4788-773X)
- Yihua Yue (ORCID: https://orcid.org/0000-0001-5474-5348)
- William H. Herman (ORCID: https://orcid.org/0000-0002-0502-674X)
- Olajide A. Adekunle (ORCID: https://orcid.org/0000-0003-2627-300X)
- Nicole Welch (ORCID: https://orcid.org/0000-0002-4655-5146)
- Victoria Criswell
- Wen Ye
- Ha T. Tran (ORCID: https://orcid.org/0000-0003-3064-0984)
Institutions
- Cleveland Clinic (US)
- University of Michigan (US)
- Cleveland Clinic Lerner College of Medicine (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.17122
- Citations
- 7
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 9.48